Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The safety of direct oral anticoagulants (DOACs) compared with warfarin in patients with both nonvalvular atrial fibrillation (AF) and clinically confirmed liver cirrhosis (LC) has not been well studied. We compared the risk of a major bleeding event between DOAC and warfarin treatments in this patient population. Methods: A total of 238 cirrhotic patients with AF were retrospectively analyzed. The major bleeding event risk was compared between DOAC- and warfarin-treated groups. The median follow-up duration was 5.6 years. Results: Among the 238 study patients with LC and AF, 128 (53.8%) received DOACs and 110 (46.2%) received warfarin. The mean patient age was 68.8 years, and 78.2% were men. A major bleeding event occurred in 10 and 20 patients in the DOAC and warfarin groups, respectively, most commonly caused by gastrointestinal bleeding (70.0%). The cumulative risk of major bleeding did not differ between the groups by log-rank test (p = 0.12). This finding did not change when using 60 propensity score-matched pairs. A multivariable Cox regression model indicated that the concomitant use of antiplatelet agents (adjusted hazard ratio [aHR], 2.06; 95% confidence interval [CI], 1.00 to 4.30; p = 0.048) and presence of esophageal or gastric varices confirmed by endoscopic examination (aHR, 2.31; 95% CI, 1.03 to 5.17; p = 0.04) were associated with major bleeding in the entire cohort. Conclusions: A major bleeding event risk is not increased by DOAC compared with warfarin treatment. Antiplatelet agent use and varices are independently associated with a higher risk of major bleeding during anticoagulation.
Abstract
Background/Aims: The safety of direct oral anticoagulants (DOACs) compared with warfarin in patients with both nonvalvular atrial fibrillation (AF) and clinically confirmed liver cirrhosis (LC) has not been well studied. We compared the risk of a major bleeding event between DOAC and warfarin treatments in this patient population. Methods: A total of 238 cirrhotic patients with AF were retrospectively analyzed. The major bleeding event risk was compared between DOAC- and warfarin-treated groups. The median follow-up duration was 5.6 years. Results: Among the 238 study patients with LC and AF, 128 (53.8%) received DOACs and 110 (46.2%) received warfarin. The mean patient age was 68.8 years, and 78.2% were men. A major bleeding event occurred in 10 and 20 patients in the DOAC and warfarin groups, respectively, most commonly caused by gastrointestinal bleeding (70.0%). The cumulative risk of major bleeding did not differ between the groups by log-rank test (p = 0.12). This finding did not change when using 60 propensity score-matched pairs. A multivariable Cox regression model indicated that the concomitant use of antiplatelet agents (adjusted hazard ratio [aHR], 2.06; 95% confidence interval [CI], 1.00 to 4.30; p = 0.048) and presence of esophageal or gastric varices confirmed by endoscopic examination (aHR, 2.31; 95% CI, 1.03 to 5.17; p = 0.04) were associated with major bleeding in the entire cohort. Conclusions: A major bleeding event risk is not increased by DOAC compared with warfarin treatment. Antiplatelet agent use and varices are independently associated with a higher risk of major bleeding during anticoagulation.
참고문헌 (32)
- Go AS, "Prevalence of diagnosed atrial fibrillation in adults : national implications for rhythm management and stroke prevention : the AnTicoagulation and Risk Factors in Atrial Fibrillation(ATRIA)Study", JAMA, 285, pp.2370~2375 (2001)
- Claeys MJ, "Summary of 2016 ESC guidelines on heart failure, atrial fibrillation, dyslipidaemia and cardiovascular prevention", Acta Cardiol, 72, pp.610~615 (2017)
- January CT, "2019 AHA", ACC, ACC, pp.HRS guideline for the management of patients with atrial fibrillation : a report of the American College of Cardiology, American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society[DOI]
- Tripodi A, "The coagulopathy of chronic liver disease", N Engl J Med, 365, pp.147~156 (2011)
- Intagliata NM, "Concepts and controversies in haemostasis and thrombosis associated with liver disease : proceedings of the 7th International Coagulation in Liver Disease Conference", Thromb Haemost, 118, pp.1491~1506 (2018)
- Kalambokis GN, "von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia", J Hepatol, 65, pp.921~928 (2016)
- Sogaard KK, "Cirrhosis is associated with an increased 30-day mortality after venous thromboembolism", Clin Transl Gastroenterol, 6, pp.e97~ (2015)
- Ambrosino P, "The risk of venous thromboembolism in patients with hepatitis C. A systematic review and meta-analysis", Thromb Haemost, 116, pp.958~966 (2016)
- Qi X, "Epidemiology of venous thromboembolism in patients with liver diseases : a systematic review and meta-analysis", Intern Emerg Med, 10, pp.205~217 (2015)
- Husted S, "Non-vitamin K antagonist oral anticoagulants(NOACs) : no longer new or novel", Thromb Haemost, 111, pp.781~782 (2014)
- Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
- Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
- Mort JF, "Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis", Clin Gastroenterol Hepatol, 19, pp.1436~1442 (2021)
- Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
- Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)
- Fu Y, "Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and liver disease : a meta-analysis and systematic review", Am J Cardiovasc Drugs, 20, pp.139~147 (2020)
- Goriacko P, "Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation", Eur J Haematol, 100, pp.488~493 (2018)
- Pastori D, "Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants", Int J Cardiol, 264, pp.58~63 (2018)
- Wang CL, "Efficacy and safety of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with impaired liver function : a retrospective cohort study", J Am Heart Assoc, 7, pp.e009263~ (2018)
- Lee HF, "Effectiveness and safety of non-vitamin K antagonist oral anticoagulant and warfarin in cirrhotic patients with nonvalvular atrial fibrillation", J Am Heart Assoc, 8, pp.e011112~ (2019)
- Lee SR, "Direct oral anticoagulants in patients with atrial fibrillation and liver disease", J Am Coll Cardiol, 73, pp.3295~3308 (2019)
- Choi J, "Risks versus benefits of anticoagulation for atrial fibrillation in cirrhotic patients", J Cardiovasc Pharmacol, 70, pp.255~262 (2017)
- Choi J, "Earlier alanine aminotransferase normalization during antiviral treatment is independently associated with lower risk of hepatocellular carcinoma in chronic hepatitis B", Am J Gastroenterol, 115, pp.406~414 (2020)
- Gage BF, "Validation of clinical classification schemes for predicting stroke : results from the National Registry of Atrial Fibrillation", JAMA, 285, pp.2864~2870 (2001)
- Lip GY, "Identifying patients at high risk for stroke despite anticoagulation : a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort", Stroke, 41, pp.2731~2738 (2010)
- Pisters R, "A novel user-friendly score(HAS-BLED)to assess 1-year risk of major bleeding in patients with atrial fibrillation : the Euro Heart Survey", Chest, 138, pp.1093~1100 (2010)
- Schulman S, "Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients", J Thromb Haemost, 3, pp.692~694 (2005)
- Hum J, "The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis", Eur J Haematol, 98, pp.393~397 (2017)
- Chai-Adisaksopha C, "Mortality outcomes in patients receiving direct oral anticoagulants : a systematic review and meta-analysis of randomized controlled trials", J Thromb Haemost, 13, pp.2012~2020 (2015)
- Serper M, "Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation", Hepatology, 73, pp.219~232 (2021)
- Eikelboom JW, "Rivaroxaban with or without aspirin in stable cardiovascular disease", N Engl J Med, 377, pp.1319~1330 (2017)
- Alexander JH, "Apixaban with antiplatelet therapy after acute coronary syndrome", N Engl J Med, 365, pp.699~708 (2011)